Press Releases

Press Releases

Date Title  
Nov 29, 2021
Prothena to Participate in JMP Securities Hematology and Oncology Summit
DUBLIN, Ireland , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will
Nov 04, 2021
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-end cash and restricted cash position was $601.5 million   Received $140 million from partner payments in third quarter from Novo Nordisk and
Oct 28, 2021
Prothena to Report Third Quarter 2021 Financial Results on November 4th
DUBLIN, Ireland , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its third quarter and first nine
Oct 01, 2021
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring two new employees, the
Oct 01, 2021
Prothena Announces Executive Appointments
Expanded roles support the continued transition to a fully integrated biotechnology company focused on rare peripheral amyloid and neurodegenerative diseases DUBLIN, Ireland , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust
Sep 03, 2021
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the
Sep 01, 2021
Prothena to Participate in Upcoming September Healthcare Conferences
DUBLIN, Ireland , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in
Aug 05, 2021
Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of 2021; quarter-end cash and restricted cash position of $402.5 million (includes $60 million payment from Roche) provides additional funding to continue
Jul 29, 2021
Prothena to Report Second Quarter 2021 Financial Results on August 5th
DUBLIN, Ireland , July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six
Jul 26, 2021
Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with subcutaneous administration Poster presentation demonstrates dual Aβ-tau vaccines simultaneously generate